Single-Dose Pharmacokinetics of Ozanimod and Its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study
figureposted on 2020-08-26, 15:47 authored by Jonathan Q. Tran, Peijin Zhang, Atalanta Ghosh, Liangang Liu, Mary Syto, Xiaomin Wang, Maria Palmisano
Article full text
The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.
The above Summary Slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.